Neuroendocrine Tumor clinical trials

Explore recruiting neuroendocrine tumor clinical trials.

Recruiting neuroendocrine tumor studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neuroendocrine Tumor trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PROSPECTIVE RANDOMIZED PHASE II STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® ([177LU]LU-DOTA-TATE) IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE TUMOR

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Dosimetry based PRRT versus standard dose PRRT with Lu-177-DOTATOC in NEN patients- a randomized study; a step towards tailored PRRT.

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II study to evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendocrine carcinomas - NEONEC D19-01

France

Therapeutic exploratory (Phase II) EU CTIS Study details

CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3

Austria, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II study to evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendocrine carcinomas - NEONEC D19-01

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) advanced GEP-NET with high disease burden (NETTER-3)

Italy, Poland, Germany, Spain, Hungary, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neuroendocrine Tumor trials by city

Neuroendocrine Tumor in Toronto Neuroendocrine Tumor in Vancouver Neuroendocrine Tumor in Montreal Neuroendocrine Tumor in Calgary Neuroendocrine Tumor in Edmonton Neuroendocrine Tumor in Ottawa Neuroendocrine Tumor in Winnipeg Neuroendocrine Tumor in Quebec City Neuroendocrine Tumor in Hamilton Neuroendocrine Tumor in Kitchener Neuroendocrine Tumor in London Neuroendocrine Tumor in Halifax Neuroendocrine Tumor in New York Neuroendocrine Tumor in Los Angeles Neuroendocrine Tumor in Chicago Neuroendocrine Tumor in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease